Format

Send to

Choose Destination
Hepatology. 2019 Jan 25. doi: 10.1002/hep.30521. [Epub ahead of print]

Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient.

Author information

1
Department of Internal Medicine, University of Pavia, and Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.
2
Unit of Palliative Care, Division of Medical Oncology, I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.
3
Division of Medical Oncology, Azienda Ospedaliero-Universitaria, Parma, Italy.

Abstract

On July 5th , 2018, the final results of the CELESTIAL trial were published on the authoritative pages of the New England Journal of Medicine (1); in this placebo-controlled, phase III trial, previously treated patients with advanced hepatocellular carcinoma (HCC) were randomized in a 2 to 1 fashion to receive either the multikinase inhibitor Cabozantinib (targeting, among the others, Vascular Endothelial Growth Factor Receptors [VEGFRs], MET, and AXL), or placebo. The study succeeded in demonstrating a reduction in the risk of death of 24% in favor of Cabozantinib; indeed, median overall survival (OS) was 10.2 months with Cabozantinib and 8.0 months with placebo (Hazard Ratio [HR] = 0.76, 95% confidence interval [CI] = 0.63 to 0.92, p=0.005) (1). This article is protected by copyright. All rights reserved.

PMID:
30681728
DOI:
10.1002/hep.30521

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center